2021
New insights on the role of vascular endothelial growth factor in biliary pathophysiology
Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Reports 2021, 3: 100251. PMID: 34151244, PMCID: PMC8189933, DOI: 10.1016/j.jhepr.2021.100251.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsVEGF/VEGFRCell biologyVascular endothelial growth factorCritical biological processesEpithelial cell biologyHIF1α-dependent mechanismEndothelial cell biologyEndothelial growth factorEpithelial cellsGrowth factorAccessory proteinsLiver repair processesCystic cellsBiological processesKinase receptorsVEGFR-2 receptorCell typesRole of VEGFBiliary developmentBiliary pathophysiologyDevelopment of cirrhosisChronic biliary diseaseBile duct proliferationPolycystic liver diseaseWound healing response
2020
Budd-Chiari Syndrome An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed
Haque LYK, Lim JK. Budd-Chiari Syndrome An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed. Clinics In Liver Disease 2020, 24: 453-481. PMID: 32620283, DOI: 10.1016/j.cld.2020.04.012.BooksConceptsBudd-Chiari syndromeLiver diseaseHepatic venous outflow obstructionPrimary Budd-Chiari syndromeDevelopment of cirrhosisVenous outflow obstructionChronic liver diseaseLife-threatening diagnosisVariable clinical presentationPortal hypertensionProthrombotic stateVenous obstructionLifelong anticoagulationMost patientsOutflow obstructionUncommon causeClinical presentationRare causeRisk factorsHepatocellular carcinomaHigh indexPatientsDiseaseSyndromeObstruction
2019
Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis
Povero D, Pinatel E, Leszczynska A, Goyal N, Nishio T, Kim J, Kneiber D, de Araujo Horcel L, Eguchi A, Ordonez P, Kisseleva T, Feldstein A. Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight 2019, 5 PMID: 31184999, PMCID: PMC6675559, DOI: 10.1172/jci.insight.125652.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell MovementCell ProliferationChemical and Drug Induced Liver InjuryChemotaxisDisease Models, AnimalExtracellular VesiclesHepatic Stellate CellsHumansInduced Pluripotent Stem CellsLiverLiver CirrhosisMaleMiceMice, Inbred C57BLMicroRNAsTranscriptomeTransforming Growth Factor betaConceptsHepatic stellate cell activationChronic liver diseaseAnti-fibrotic effectsStellate cell activationLiver fibrosisLiver diseaseExtracellular vesiclesInduced pluripotent stem cellsCell activationDuct ligation-induced liver fibrosisFlow cytometryAnti-fibrotic approachesDevelopment of cirrhosisPro-fibrogenic responseProgression of fibrosisStem cell-derived extracellular vesiclesAnti-fibrotic strategiesCharacterization of iPSCsGreatest unmet needCell-derived extracellular vesiclesMiR-92a-3pWound healing responseStem cellsIPSC-EVsLiver injury
2015
Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Butt AA, Yan P, Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine 2015, 175: 178-185. PMID: 25485735, PMCID: PMC5017246, DOI: 10.1001/jamainternmed.2014.6502.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisLiver fibrosis progressionHepatic decompensation eventsDevelopment of cirrhosisFibrosis progressionHCV controlHepatic decompensationDecompensation eventsLiver fibrosisNegative HCV antibody test resultPositive HCV RNA test resultLower mean body mass indexHCV antibody test resultHCV RNA test resultsNational Veterans Affairs databaseHepatitis C virus infectionMean body mass indexHigher serum aminotransferase levelsHCV Infected VeteransRNA test resultsC virus infectionFIB-4 scoreFibrosis-4 indexSerum aminotransferase levelsMonths of follow
2012
PPARα activation in portal hypertension
Liu H, Lee S, Groszmann R, Iwakiri Y, Taddei T. PPARα activation in portal hypertension. Hepatology 2012, 56: 1993-1995. PMID: 23115009, DOI: 10.1002/hep.26045.Peer-Reviewed Original ResearchHepatic endothelial cellsHepatic endothelial dysfunctionPortal blood flowPortal hypertensionCyclo-oxygenase-1PPARa activatorPortal pressureSirius Red staining of liver sectionsEndothelial dysfunctionHepatic fibrosisVasodilatory response to acetylcholineRats treated with fenofibrateStaining of liver sectionsResponse to acetylcholineTreated with vehicleDevelopment of cirrhosisSmooth muscle actinCollagen I mRNA expressionNitric oxideCyclo-oxygenase-1 expressionAcetylcholine (AChCirrhotic rat liversOral fenofibrateCirrhotic ratsCGMP levelsIntestinal and plasma VEGF levels in cirrhosis: the role of portal pressure
Huang H, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, Iwakiri Y. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. Journal Of Cellular And Molecular Medicine 2012, 16: 1125-1133. PMID: 21801303, PMCID: PMC3213314, DOI: 10.1111/j.1582-4934.2011.01399.x.Peer-Reviewed Original ResearchConceptsPlasma VEGF levelsPortal pressureVEGF levelsPortal hypertensionIntestinal VEGFDevelopment of cirrhosisFibrosis/cirrhosisAge-matched controlsGroups of ratsEnd of exposureCirrhosisRatsSignificant positive correlationWeeksHypertensionVEGFInhalationPositive correlationDifferent stagesCarbon tetrachlorideLevelsPathologyControlManagement of chronic hepatitis C infection in children
Porto AF, Tormey L, Lim JK. Management of chronic hepatitis C infection in children. Current Opinion In Pediatrics 2012, 24: 113-120. PMID: 22157364, DOI: 10.1097/mop.0b013e32834eb73f.Peer-Reviewed Original ResearchConceptsChronic hepatitis C infectionHepatitis C infectionC infectionPeginterferon αAntiviral therapyLiver fibrosisGenotype 1Global public health burdenDevelopment of cirrhosisSustained virologic responseIndolent clinical courseLarge prospective studiesProgressive liver fibrosisPublic health burdenImportant clinical implicationsMajority of childrenAreas of controversyVirologic responseViral eradicationCombination regimensInfected childrenClinical courseProspective studyTreatment courseEarly treatment
2011
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension
Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver International 2011, 32: 199-213. PMID: 21745318, PMCID: PMC3676636, DOI: 10.1111/j.1478-3231.2011.02579.x.BooksConceptsLiver sinusoidal endothelial cellsPortal hypertensionEndothelial dysfunctionArterial vasodilationPortosystemic collateral vesselsProduction of vasodilatorsDevelopment of cirrhosisCollateral vessel formationPathological vascular eventsSinusoidal endothelial cellsExtrahepatic circulationIntrahepatic resistanceOesophageal varicesVascular eventsVascular resistanceVasodilator moleculeCollateral vesselsSinusoidal microcirculationPortal veinHypertensionSystemic circulationBlood flowCirrhosisDysfunctionNitric oxide
2008
Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients. The Journal Of Rheumatology 2008, 35: 2159-2164. PMID: 18793002, DOI: 10.3899/jrheum.080336.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEndstage liver diseaseLiver diseasePortal hypertensionLiver involvementViral hepatitisLupus erythematosusLiver disease-free survivalNonalcoholic fatty liver diseaseCoexistent liver diseaseSubclinical liver involvementDevelopment of cirrhosisLiver enzyme abnormalitiesAlanine aminotransferase levelsDisease-free survivalRetrospective chart reviewCohort of patientsFatty liver diseasePrimary biliary cirrhosisAlkaline phosphatase levelsClinical diagnostic groupsAutoimmune hepatitisCryptogenic cirrhosisHepatitis CAminotransferase levels
2007
Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS).
Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS). In Vivo 2007, 21: 957-65. PMID: 18210741.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsBile duct ligationLiver fibrosisDuct ligationPurinergic receptorsCommon bile duct ligationEffect of PPADSPurinergic receptor inhibitorsDevelopment of cirrhosisHSC proliferationEffective pharmacologic treatmentExperimental liver fibrosisAnnexin V flow cytometryEffect of suraminSirius red stainQuantitative RT-PCRPharmacologic treatmentReceptor inhibitorsPPADSStellate cellsLiver sectionsFibrosisBromodeoxyuridine uptakePurinoceptor activationExperimental animals
2005
Hepatocellular Carcinoma in Type 1 Gaucher Disease: A Case Report with Review of the Literature
Xu R, Mistry P, Mckenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel M. Hepatocellular Carcinoma in Type 1 Gaucher Disease: A Case Report with Review of the Literature. Seminars In Liver Disease 2005, 25: 226-229. PMID: 15918150, DOI: 10.1055/s-2005-871201.Peer-Reviewed Original ResearchConceptsType 1 Gaucher diseaseHepatocellular carcinomaGaucher diseaseLiver transplantationInborn errorsType 1 Gaucher's diseaseNecessitating liver transplantationNon-neuronopathic diseaseDevelopment of cirrhosisMajority of patientsStandard of careRisk of malignancyEnzyme replacement therapyDeficiency of glucocerebrosidaseRare inborn errorVariety of neoplasmsAutosomal recessive disorderMarrow infiltrationPulmonary diseaseSupplemental therapyReplacement therapyCase reportLysosomal storage diseaseTissue macrophagesType 2
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplant
2003
Comparative study of Hepatitis C virus genotypes 1 and 3 in Salvador, Bahia
Codes L, de Freitas L, Jesus R, Vitvitski L, Silva L, Trepo C, Reis M, Paraná R. Comparative study of Hepatitis C virus genotypes 1 and 3 in Salvador, Bahia. The Brazilian Journal Of Infectious Diseases 2003, 7: 409-417. PMID: 14636481, DOI: 10.1590/s1413-86702003000600009.Peer-Reviewed Original ResearchConceptsHepatitis C virusC virusMost patientsSubtype 3aAverage agePositive anti-HCV resultsAnti-HCV resultsNecro-inflammatory activityDevelopment of cirrhosisOutpatient medical recordsSignificant differencesIllicit drug useMETAVIR classificationThyroid dysfunctionYounger patientsHistopathological findingsInflammatory activityLymphoid folliclesEpidemiological characteristicsRNA-HCVGenotype 3Medical recordsSubtype 1bAlcohol consumersGenotype 1
2002
A patient with autoimmune hepatitis type I, Addison's disease, atrophic thyroiditis, atrophic gastritis, exocrine pancreatic insufficiency, and heterozygous α1-antitrypsin deficiency
Bergwitz C, Trautwein C, Brabant G, Manns MP. A patient with autoimmune hepatitis type I, Addison's disease, atrophic thyroiditis, atrophic gastritis, exocrine pancreatic insufficiency, and heterozygous α1-antitrypsin deficiency. The American Journal Of Gastroenterology 2002, 97: 1050. PMID: 12003388, DOI: 10.1111/j.1572-0241.2002.05628.x.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionAtrophic gastritisAutoimmune hepatitisAddison's diseaseAlcohol consumptionAssociation of autoimmune hepatitisAutoimmune hepatitis type IHeterozygous alpha1-antitrypsin deficiencyHeterozygous α1-Antitrypsin DeficiencyHistory of Addison's diseaseSerum alpha1-antitrypsin levelsDiagnosis of autoimmune hepatitisDecompensated liver cirrhosisDevelopment of cirrhosisSevere atrophic gastritisAdditional risk factorsAlpha1-antitrypsin deficiencyAlpha1-antitrypsin levelsΑ1-antitrypsin deficiencyAlpha1-antitrypsin geneExocrine pancreatic insufficiencyAtrophic thyroiditisHydrocortisone therapyAdrenal insufficiencyLiver biopsy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply